DUTASTERIDE 0.1% + PYRILUTAMIDE 0.5%
DUTASTERIDE 0.1% / PYRILUTAMIDE 0.5%
Dual-compound, solvent-based topical research formulation developed for localized, non-clinical 5α-reductase pathway and androgen receptor interaction studies.
Prefer email communication?
Request this formulation via our consultation form.
Request-only supply. No instant checkout. All formulation requests are reviewed before fulfilment.
Technical Data
Chemical Identification
Physicochemical Characteristics
Documentation & Analytical Data
Research Documentation
Formulation Specification
Concentration system:
Equivalent concentration:
Total active content:
Vehicle system: Ethanol 96% (Ph. Eur.) / Propylene Glycol (Ph. Eur.) / Diethylene Glycol Monoethyl Ether — Transcutol® P (Ph. Eur.) / Dimethyl Isosorbide
Solvent ratio: 45 / 12.5 / 32.5 / 10
Formulation architecture: Multi-solvent topical carrier system designed to support compound solubility, formulation consistency, and controlled surface application modeling.
Water content: No added water
Formulation complexity:
Research Context
Storage & Handling
Storage range: 2–8°C preferred; 15–25°C acceptable for short-term controlled handling.
Storage conditions: Store tightly closed in a cool, dry, dark environment.
Light sensitivity: Protect from direct sunlight and UV exposure.
Temperature stability: Avoid freezing and excessive heat exposure.
Air exposure: Minimize prolonged exposure to air.
Closure requirement: Keep container tightly sealed when not in use.
Stability context: Storage conditions are intended to support solvent balance, formulation consistency, and compound integrity during controlled non-clinical handling.
Research Use Notice
Supplied exclusively for laboratory research and analytical applications.
Not intended for therapeutic, cosmetic, veterinary, food, household, diagnostic, or human application.
Handling should occur within qualified non-clinical research environments only.
Overview
Finasteride + Pyrilutamide is a dual-compound topical research formulation investigated within controlled non-clinical environments involving localized androgen pathway modulation and androgen receptor-related interaction models.
Within topical research frameworks, Finasteride is commonly examined for its interaction with localized 5α-reductase-related signaling pathways, while Pyrilutamide is investigated in experimental models involving localized androgen receptor interaction and surface-confined compound behavior.
Experimental focus is generally directed toward localized biochemical interaction behavior, compound compatibility within multi-solvent carrier systems, and controlled delivery architecture associated with topical research formulations.
Research applications emphasize surface-confined topical carrier systems designed to support formulation consistency, compound dispersion behavior, and localized exposure modeling within controlled laboratory environments.
This formulation is presented as a research-grade topical solution intended exclusively for scientific, analytical, and laboratory-based investigation under appropriately controlled non-clinical handling conditions.
